Stinginn, LLC
Miami, FL
- UEI
- PJV5A55KF6T5
- CAGE
- 82YB7
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 13520 SW 99th Ct, Miami, FL 33176, USA
- Website
- stinginn.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Oncosting, LLC | Baltimore, MD | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Novab, Inc. | Tucker, GA | 621511 Medical Laboratories |
| Inimmune Corp | Missoula, MT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Oncotrap Inc. | Chapel Hill, NC | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| 7 Hills Pharma Inc. | Houston, TX | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Stinginn, LLC is a U.S. company that specializes in harnessing the innate immune system to combat infectious disease, inflammation, and cancer through the use of STING signaling and related technologies. Through federal grants, Stinginn, LLC has focused on developing novel STING agonists and antagonists for cancer treatment and anti-inflammatory therapeutics.
Specifically, Stinginn, LLC has received federal funding to develop superior STING agonists compared to existing cyclic dinucleotides, which can help stimulate anti-tumor immune responses for cancer treatment when administered systemically. Additional federal grants have supported Stinginn's development of a vaccine against Human T-cell leukemia virus type-1 (HTLV-1) using a Vesicular Stomatitis Virus (VSV) vector. Stinginn, LLC has also conducted research under federal grants on STING inhibitory compounds to evaluate their potential as anti-inflammatory therapeutics. These federal grants have been awarded by the National Institutes of Health, including the National Cancer Institute and National Institute of Allergy and Infectious Diseases. Stinginn, LLC has partnered with the University of Miami School of Medicine on several of these federally-funded research projects.
Quick answers
Is Stinginn, LLC registered in SAM.gov?
Yes. Stinginn, LLC's SAM.gov registration is active through October 27, 2026.
What is Stinginn, LLC's most recent federal award?
Stinginn, LLC's most recent federal grant award is Human specific sting agonists for the treatment of cancer (R41CA275637), from National Cancer Institute (NIH), on August 1, 2023.
On GovTribe
See Stinginn, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors